WCM Investment Management LLC Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

WCM Investment Management LLC grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 110.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,977 shares of the biotechnology company’s stock after purchasing an additional 12,060 shares during the period. WCM Investment Management LLC’s holdings in Sarepta Therapeutics were worth $2,785,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of SRPT. Sumitomo Mitsui Trust Group Inc. lifted its position in Sarepta Therapeutics by 13.5% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,930 shares of the biotechnology company’s stock valued at $235,000 after buying an additional 230 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Sarepta Therapeutics by 9.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,570 shares of the biotechnology company’s stock worth $797,000 after acquiring an additional 568 shares during the last quarter. Yorktown Management & Research Co Inc purchased a new position in shares of Sarepta Therapeutics during the 4th quarter worth approximately $559,000. Retirement Systems of Alabama increased its holdings in Sarepta Therapeutics by 0.3% in the 4th quarter. Retirement Systems of Alabama now owns 116,145 shares of the biotechnology company’s stock valued at $14,122,000 after purchasing an additional 299 shares during the last quarter. Finally, abrdn plc increased its holdings in Sarepta Therapeutics by 6.2% in the 4th quarter. abrdn plc now owns 457,695 shares of the biotechnology company’s stock valued at $55,294,000 after purchasing an additional 26,597 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on SRPT shares. Piper Sandler lowered their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Jefferies Financial Group began coverage on Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research note on Monday, January 27th. Royal Bank of Canada reissued an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Finally, HC Wainwright reaffirmed a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, January 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $178.71.

Insider Activity

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now owns 5,880 shares of the company’s stock, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $112.74 on Tuesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 1-year low of $102.15 and a 1-year high of $173.25. The stock has a market cap of $10.77 billion, a PE ratio of 90.19 and a beta of 0.75. The firm has a fifty day moving average price of $120.82 and a 200 day moving average price of $125.57.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.